TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2576663

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 micrograms/h in 100 ml saline)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 14
Study: 818827

Group type: EXPERIMENTAL
Intervention: Prednisolone and isoniacid for 6 or 12 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 92
Study: 31802697

Group type: EXPERIMENTAL
Intervention: Healthy Body Image (HBI) intervention
Number of subjects: 2446

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2446
Study: 31553469

Group type: EXPERIMENTAL
Intervention: Light therapy plus CBT
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham therapy plus CBT
Number of subjects: 102
Study: 29168787

Group type: EXPERIMENTAL
Intervention: FRED game (exergame)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no physical activity)
Number of subjects: 40
Study: 25261425

Group type: EXPERIMENTAL
Intervention: Electrical stimulation group (18-32 minutes of pulsed current, stimulation frequency of 80 Hz, pulse duration of 200 μs, stimulation intensity fixed near the maximal tolerated)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined group (electrical stimulation and low-level laser therapy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Laser group (low-level laser therapy dose of 4-6 J per point, six points at the knee joint)
Number of subjects: 45
Study: 24195208

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment with disperse-dense wave applied at specific acupuncture points (Taiyang, Xiaguan, Heliao)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment
Number of subjects: 68
Study: 22053565

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB) 1.25 mg/0.05 ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT)
Number of subjects: 60
Study: 19447807

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Optimized anti-arrhythmic drug (AAD) therapy
Number of subjects: 260
Study: 16510648

Group type: EXPERIMENTAL
Intervention: Removable splint
Number of subjects: 113

Group type: COMPARATOR
Intervention: Short arm cast
Number of subjects: 113
Study: 15178990

Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1500
Study: 11269583

Group type: EXPERIMENTAL
Intervention: Eccentric calf muscle training for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Concentric calf muscle training for 12 weeks
Number of subjects: 44
Study: 9443527

Group type: EXPERIMENTAL
Intervention: 10 mg dose of diazepam
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 8504712

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patches (0.05 mg daily estradiol) with medroxyprogesterone acetate (5 mg orally for 14 days per month)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calcium group (500 mg calcium daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Transdermal estrogen vs. calcium
Number of subjects: 38
Study: 3673928

Group type: EXPERIMENTAL
Intervention: 65 mg/d AA intake for 2 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 5 mg/d AA intake for 4 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 605 mg/d AA intake for 3 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 5 mg/d AA intake for 4 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 605 mg/d AA intake for 4 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 65 mg/d AA intake for 3 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: AA intake calculated to maintain plasma AA levels of at least 0.4 mg/dL (23 mumol/L)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Average AA intake estimated to maximize total body pool
Number of subjects: 11

Group type: COMPARATOR
Intervention: Urinary AA levels
Number of subjects: 11

Group type: COMPARATOR
Intervention: Salivary AA levels
Number of subjects: 11
Study: 29300728

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (IIT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 10
Study: 27002277

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 326

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 326
Study: 23828313

Group type: EXPERIMENTAL
Intervention: Topical nasal anesthetic (TNA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 23116451

Group type: EXPERIMENTAL
Intervention: Settled swine facility organic dust extract (ODE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peptidoglycan (PGN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified whole blood assay (WBA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sputum inflammatory markers (TNF‐α, IL‐8, IL‐6, IL‐10)
Number of subjects: 0
Study: 20855984

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 7
Study: 18641546

Group type: EXPERIMENTAL
Intervention: Fixed-dose mycophenolate mofetil (MMF)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Concentration-controlled MMF therapy
Number of subjects: 332

Group type: COMPARATOR
Intervention: Tacrolimus treatment
Number of subjects: 332

Group type: COMPARATOR
Intervention: Cyclosporine treatment
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Patients with diarrhea
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Patients without diarrhea
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: -840G>A UGT2B7 SNP
Number of subjects: 332
Study: 15914521

Group type: EXPERIMENTAL
Intervention: Weight loss (50% reduction overweight by caloric restriction)
Number of subjects: 11
Study: 12629233

Group type: EXPERIMENTAL
Intervention: Cross-modal stimuli (visual and tactile)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Unimodal stimuli (tactile or visual)
Number of subjects: 18
Study: 10334216

Group type: EXPERIMENTAL
Intervention: Glottic reconstruction with false vocal fold (FVF) mucosal flap
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard frontolateral partial laryngectomy (FLPL) without glottic reconstruction
Number of subjects: 27
Study: 7489171

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 299

Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 299
Study: 1850946

Group type: EXPERIMENTAL
Intervention: Oral diazepam, 5 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oral diazepam, 10 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oral midazolam, 15 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 95
Study: 6786536

Group type: EXPERIMENTAL
Intervention: 4 mg of folic acid a day before and during early pregnancy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study: 31415123

Group type: EXPERIMENTAL
Intervention: Long-term low-dose clarithromycin (CAM) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no clarithromycin therapy)
Number of subjects: 28
Study: 29334438

Group type: EXPERIMENTAL
Intervention: Stabilized 0.454% stannous fluoride dentifrice with zinc citrate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice
Number of subjects: 80

Group type: COMPARATOR
Intervention: Negative control fluoride dentifrice
Number of subjects: 80
Study: 26073493

Group type: EXPERIMENTAL
Intervention: Lanreotide (90 mg every 4 weeks) for 6 months
Number of subjects: 59
Study: 23147275

Group type: EXPERIMENTAL
Intervention: Beating Heart Problems programme (8-week group programme based on cognitive behaviour therapy and motivational interviewing)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study: 22703478

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 57
Study: 19938654

Group type: EXPERIMENTAL
Intervention: Writing about emotionally dissonant experiences for three weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (without writing)
Number of subjects: 20
Study: 17336229

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg intravenously three times daily for 5 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (saline administered in equal volume)
Number of subjects: 19
Study: 15111377

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (4 mg/patch) twice weekly for 6 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 11930721

Group type: EXPERIMENTAL
Intervention: Chlorhexidine Chip (CHX) following scaling and root planing (SRP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 65
Study: 9559377

Group type: EXPERIMENTAL
Intervention: Noninvasive estimation of left ventricular stroke volume including zero velocity flow
Number of subjects: 40

Group type: COMPARATOR
Intervention: Doppler stroke distance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Doppler stroke distance and long axis motion
Number of subjects: 40
Study: 7942720

Group type: EXPERIMENTAL
Intervention: Functional bowel disorder (FBD) in women with dysmenorrhea (DYS)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control group (women without dysmenorrhea)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Neuroticism scores
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Bowel symptoms
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Painful menses and water retention
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Prostaglandin levels
Number of subjects: 383
Study: 3221029

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 2184564

Group type: EXPERIMENTAL
Intervention: Cisplatin alone, modified MVAC scheme, or combination of cisplatin and methotrexate (3 cycles)
Number of subjects: 52
Study: 22216504

Group type: EXPERIMENTAL
Intervention: Frusemide (120 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31673858

Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive (TFA) system (n = 35)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Reciproc system (n = 29)
Number of subjects: 64
Study: 30658699

Group type: EXPERIMENTAL
Intervention: Treatment escalation (initial prednisone and methotrexate, changed every 4 months)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Treatment tapering (tapering MTX)
Number of subjects: 381

Group type: COMPARATOR
Intervention: No treatment (no DFR)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Drug-free remission (DFR)
Number of subjects: 381
Study: 28298021

Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine (1-2 mg/hour) and hydroxyethyl starch (HES) from the day before surgery until the 7th postoperative day
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Parenteral nimodipine and HES
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 182
Study: 25498787

Group type: EXPERIMENTAL
Intervention: Self-affirmation (writing about a core personal value)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulting evaluative feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral evaluative feedback
Number of subjects: 0
Study: 23343649

Group type: EXPERIMENTAL
Intervention: Continuous tranexamic acid (TA) dosing: 10 mg/kg followed by an infusion of 1 mg·kg·h(‐1) throughout the operation, and 10 mg/kg into the CPB.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Discontinuous tranexamic acid (TA) dosing: 10 mg/kg, then 10 mg/kg into the CPB and 10 mg·kg·h(‐1) at the end of CPB.
Number of subjects: 21
Study: 21112921

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group maintaining usual lifestyle behavior
Number of subjects: 29
Study: 19242355

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5 mg atorvastatin
Number of subjects: 36
Study: 17381945

Group type: EXPERIMENTAL
Intervention: Western advertising and media exposure
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: General eating styles
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Body esteem levels
Number of subjects: 800
Study: 15281543

Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 81

Group type: COMPARATOR
Intervention: LMA
Number of subjects: 81
Study: 11583768

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9156415

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin)
Number of subjects: 50
Study: 7961015

Group type: EXPERIMENTAL
Intervention: Whole abdominal irradiation using a four orthogonal field's technique (30 grays, 1.5 Gy/fraction/day, 20 fractions over 30 days)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Whole abdominal irradiation with a four orthogonal field's technique
Number of subjects: 167
Study: 3651280

Group type: EXPERIMENTAL
Intervention: Fentanyl 2.5 micrograms kg‐1 i.v.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buprenorphine 7.5 micrograms kg‐1 i.v.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 30042471

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling (four sessions)
Number of subjects: 492
Study: 28262529

Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine 2.5mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide 20mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of neostigmine and metoclopramide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 90
Study: 25252602

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by surgery (Arm B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Primary surgery (Arm A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by surgery (Arm B) after tumor resection
Number of subjects: 66

Group type: COMPARATOR
Intervention: Primary surgery (Arm A) after tumor resection
Number of subjects: 66
Study: 24180552

Group type: EXPERIMENTAL
Intervention: Tomato juice (4 oz)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tomato juice (8 oz)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tomato juice (12 oz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no tomato juice)
Number of subjects: 20
Study: 21223267

Group type: EXPERIMENTAL
Intervention: Self-event connections that were positive and about stable aspects of the self
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Shared self-event connections
Number of subjects: 130
Study: 18688808

Group type: EXPERIMENTAL
Intervention: Naltrexone (opiate blocker) administered in a double-blind, crossover design for 7 weeks with an additional 14 hr/week of observation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher morning levels of B-endorphin relative to ACTH
Number of subjects: 36
Study: 17044955

Group type: EXPERIMENTAL
Intervention: Adapted spoons with thickened handles (diameters of 1, 3, and 5cm) filled with water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adapted spoons with thickened handles (diameters of 1, 3, and 5cm) filled with sugar
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (12 healthy comparison participants; 4 males, 8 females; mean age 25y 6mo [SD 3y 0mo]; range 20y 0mo‐30y 0mo)
Number of subjects: 10
Study: 12551734

Group type: EXPERIMENTAL
Intervention: Lavandula tincture (1:5 in 50% alcohol) 60 drops/day plus placebo tablet (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Imipramine 100 mg/day plus placebo drop (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Imipramine 100 mg/day plus lavandula tincture 60 drops/day (Group C)
Number of subjects: 45
Study: 10546926

Group type: EXPERIMENTAL
Intervention: 75 microg filgrastim
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 150 microg filgrastim
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 microg filgrastim
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: filgrastim (all doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: filgrastim
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 8934063

Group type: EXPERIMENTAL
Intervention: 20 micrograms EE + 75 micrograms gestodene
Number of subjects: 58

Group type: COMPARATOR
Intervention: 30 micrograms EE + 75 micrograms gestodene
Number of subjects: 58
Study: 1991883

Group type: EXPERIMENTAL
Intervention: Sodium chloride 11.7%
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Increasing concentrations of hypertonic saline
Number of subjects: 600
Study: 6838746

Group type: EXPERIMENTAL
Intervention: Intraoperative methadone 10 mg i.v. at induction of anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative methadone 10 mg i.v. following operation
Number of subjects: 0
Study: 28516874

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 290
Study: 27734219

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg plus caffeine 65 mg (test)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg (reference)
Number of subjects: 26
Study: 25156114

Group type: EXPERIMENTAL
Intervention: HIV-infected patients on HAART
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: HIV patients not on HAART (non-HAART)
Number of subjects: 574

Group type: COMPARATOR
Intervention: HIV-uninfected patients (HIV(-)TB(+))
Number of subjects: 574
Study: 22505700

Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFPP) in combination with leflunomide and methotrexate (MTX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leflunomide plus methotrexate (no-DFPP group)
Number of subjects: 60
Study: 21102997

Group type: COMPARATOR
Intervention: Doxepin 3 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Doxepin 1 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Doxepin 1 mg and 3 mg
Number of subjects: 240
Study: 18202421

Group type: EXPERIMENTAL
Intervention: Disease Control Rate (DCR) at week 8
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Complete Response (CR) or Partial Response (PR) at week 8
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Disease Control Rate (DCR)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Median survival times
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Median time to response, time to progression, and survival time
Number of subjects: 984
Study: 15941876

Group type: EXPERIMENTAL
Intervention: Moderate-fat, moderate-carbohydrate diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate hypoenergetic diet (‐600 kcal/d)
Number of subjects: 40
Study: 12641399

Group type: EXPERIMENTAL
Intervention: SP monotherapy
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: SP/CQ combination therapy
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: SP/AQ combination therapy
Number of subjects: 448
Study: 10462143

Group type: EXPERIMENTAL
Intervention: Cilnidipine (CNP) 10 mg/day
Number of subjects: 35
Study: 7607610

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal population (baseline comparison)
Number of subjects: 0
Study: 2088249

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg orally, 8 hourly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (placebo tablet thrice daily)
Number of subjects: 80
Study: 41544

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg at night
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31751687

Group type: EXPERIMENTAL
Intervention: Inonotus obliquus polysaccharides (IOP) at a dosage of 50 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Compound C (chemical inhibitor of AMPK)
Number of subjects: 0
Study: 31374046

Group type: EXPERIMENTAL
Intervention: Ethosuximide for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Escitalopram (or another antidepressant) for 4 weeks after initial treatment
Number of subjects: 40
Study: 29390284

Group type: EXPERIMENTAL
Intervention: HPMC 2%
Number of subjects: 149
Study: 26285326

Group type: EXPERIMENTAL
Intervention: Therapeutic physical exercises designed to treat pneumonia considering myofascial disorders
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional therapeutic physical exercises
Number of subjects: 134
Study: 22520627

Group type: EXPERIMENTAL
Intervention: Essential oil solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Water irrigation
Number of subjects: 35
Study: 21035822

Group type: EXPERIMENTAL
Intervention: Intensive weight loss intervention
Number of subjects: 212
Study: 19471158

Group type: EXPERIMENTAL
Intervention: Flow Dilution (FD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: In-line Dialysance (DD)
Number of subjects: 48
Study: 17355761

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-obese adults
Number of subjects: 2
Study: 15325927

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40